Additionally, compared to the control group,the cancer group had a significantly lower FSH level (12.52 ± 4.17 vs. 13.35 ± 4.84, P=0.006) and a thinner endometrium (10.16 ± 3.11 vs. 10.84 ± 2.17, P<0.001) on the trigger day (Table 2). Here, BRD2 is linked to cancer.